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Bladder cancer is the second most frequent urological malignancy
in North America (Parker et al, 1996), and the most common
urological cancer in Southeast Asia. More than 90% of patients
diagnosed with bladder cancer have transitional cell carcinoma
(TCC) (Lamm et al, 1996). Patients with superficial tumours
(carcinoma in situ [CIS], Ta, T1) account for 70–85% of all newly
diagnosed cases (Whitmore, 1988; Lamm, 1992). The first choice
of treatment for stages Ta and T1 disease is transurethral resection
(TUR). A major problem in the treatment of superficial TCC of the
bladder is the high incidence of tumour recurrence following TUR.
In addition to the multifocal origin of these tumours, a further
explanation for this high rate of recurrence might be the implanta-
tion of tumour cells at the time of resection. In follow-up, patients
need periodic cystoscopic examinations and adjuvant intravesical
(i.b.) therapies to prevent or postpone tumour recurrence
(Grossman et al, 1996). Furthermore, the diagnosis and effective
treatment of bladder CIS remain dilemmas.
A suitable bladder tumour model that resembles human disease
both histologically and in behaviour is essential for evaluating new
therapeutic agents and modalities. The ideal animal bladder
tumour model should include the following characteristics:
1. The tumour should grow intravesically (orthotopically), such
that the tumour can be directly exposed to i.b. antitumour
drugs in its natural environment.
2. The tumour should be of pure TCC origin, with different
stages of disease progression (CIS, papillary and invasive
diseases) and, as for the human disease, the majority of the
tumours should be superficial, but not progressive.
3. The animal host should be immunocompetent and reasonably
large, so it can be treated by various antitumour modalities
such as immunotherapy with bacillus Calmette–Guérin (BCG),
chemotherapy, and whole bladder photodynamic therapy
(PDT).
4. The tumour should be technically easy to develop within a
reasonable time period, and highly reproducible with respect
to its natural history.
Rodent primary bladder tumours have been induced by N-[4-(5-
nitro-2-furyl)-2-thiazolyl]formamide (FANFT) and other carcino-
gens for 30 years (Erturk et al, 1967, 1969, 1970; Soloway, 1977;
Arai et al, 1979; Ibrahiem et al, 1983; Ohtani et al, 1986; Samma
et al, 1990). The induction of primary bladder tumours required
8–11 months, with both TCC and squamous carcinoma induced by
carcinogen ingestion (Erturk et al, 1967, 1969, 1970; Herman et al,
1985; Ohtani et al, 1986; Oyasu, 1995; Stocker et al, 1997). A
transplantable animal model appears more feasible as an experi-
mental tool for testing new antineoplastic agents. Soloway (1977)
showed that bladder tumour cells (MBT-2) could be implanted on
the murine bladder mucosa by i.b. tumour inoculation, if the
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bladder mucosa was pretreated with N-methyl-N-nitrosourea
(MNU). Ibrahiem and colleagues (1983) injected rat tumour cells
into rat bladder muscularis to develop an invasive bladder tumour
model, because of tumour cell growth failure when inoculated on
the bladder mucosa using Soloway’s procedure. Chin et al (1991)
established an orthotopic mouse bladder tumour model by
implanting MBT-2 tumour cells on bladder mucosa, which was
altered by mild acid pretreatment. Compared with Soloway’s proce-
dure, the one used by Chin et al was more convenient. Carcinogen
could be avoided and higher tumour takes (75–80%) were achieved
(Chin et al, 1991). The advantages and limitations of previous
animal bladder tumour models were recently reviewed by Oyasu
(1995). In mice, most of the deeply invasive bladder tumours were
squamous cell carcinomas, as opposed to TCC. The carcinomas
observed in mice tended to invade into the perivesical organs by
direct extension, and seldom showed metastasis to regional lymph
nodes or lung as observed in humans. The rat models, however,
were more closely parallel to human bladder carcinomas than mouse
models in regards to configuration and progression (Oyasu, 1995).
Therefore we adapted the procedure described by Chin et al (1991)
by instilling AY-27 TCC cells into syngeneic rat bladders, and moni-
toring for tumour growth with magnetic resonance imaging (MRI)
at weekly intervals. This resulted in efficient establishment of
various stages of TCC within a relatively short time period. This
orthotopic rat bladder TCC model resembles the human situation
resulting from ‘seeding’ of viable tumour cells. Its characteristics
and application potentials are discussed.
MATERIALS AND METHODS
Tumour cells and culture conditions
Fischer F344 rats were used to establish the orthotopic bladder
tumour model and to propagate the tumour heterotopically (flank
or subcutaneous). The rat bladder TCC cell line AY-27 was estab-
lished as a primary bladder tumour in Fischer F344 rats by feeding
FANFT, and was generously provided by Dr Steve Selman at the
Medical College of Ohio, Toledo. The cells were initiated from
frozen stock and cultured in vitro as monolayers at 37°C in a
humidified atmosphere of 5% carbon dioxide in air. RPMI-1640
medium (Gibco-BRL) supplemented with 10% fetal bovine
serum, penicillin–streptomycin and 2.0 g l–1 sodium bicarbonate,
was used throughout. Cells were passaged when nearly confluent
by standard, limited trypsinization procedures.
Preparation of cells
Single tumour cell suspensions were prepared by mincing the
tumour under sterile conditions and plating in sterile plastic T-25
flasks (Corning, NY, USA). The medium was decanted from the
adherent cells and replaced with fresh medium 4 h later, and at
daily intervals for 3–4 days. When the plated cells neared conflu-
ence, the growth medium was removed and the cells were incu-
bated for 10 min in Hank’s balanced salt solution (HBSS) without
Ca++ and Mg++, supplemented with EDTA (ethylenediamine-
tetraacetic acid, 200 mgl–1, Sigma Chemicals) and antibiotic as
above. HBSS was replaced by 0.01% trypsin–EDTA in HBSS and
incubated for 10 min. The resulting cell suspension was then
centrifuged at 75 g for 5 min, the supernatant discarded and the
cells resuspended in 10 ml HBSS with Ca2+ and Mg2+. Cell 
number was determined with a Coulter Counter (Coulter
Industries, Model ZBI). Cell suspension directly from cell culture
was used for both bladder instillation and subcutaneous injection.
For orthotopic implantation, 1.5 ´ 106 cells in 0.5 ml HBSS were
instilled intravesically. For flank implantation, 1.0 ´ 106 cells in
100 ml HBSS were injected subcutaneously. To maintain the
phenotypic and cytogenetic fidelity, the AY-27 TCC cell line was
passaged periodically as subcutaneous tumours in the flanks of
Fischer F344 rats. A tumour cell stock was maintained by cryop-
reservation.
Animals
Fischer F344 rats were obtained from Charles River, Canada, and
subsequently bred locally in our vivarium. Only female rats
(160–200 g) were recipients for the orthotopic bladder inocula-
tion; male Fischer F344 rats were utilized for the flank implanta-
tion. All animal procedures were performed in compliance with
the Canadian Council on Animal Care Guidelines. Sterile tech-
nique was used for tumour cell implantation.
Tumour implantation
Intravesical instillation of the TCC cell suspension followed that
described by Chin et al (1991). Briefly, the rats were anaesthetized
with intraperitoneal (i.p.) injections of ketamine (50 mg kg–1 body
weight, MTC Pharmaceuticals, Cambridge, Ontario, Canada) and
xylazine (7.5 mg kg–1 body weight, Miles Canada Inc. Etobicoke,
Ontario, Canada). Body temperature was maintained with a
homeothermic blanket. The rat bladder was catheterized via the
urethra with an 18-gauge plastic intravenous (i.v.) cannula (Becton
Dickinson, UT, USA). The 18-gauge cannula was optimal for
administration of the various agents, providing a snug fit, with no
leakage around the catheter. To facilitate tumour seeding, the
bladder mucosa was conditioned with an acid rinse. The condi-
tioning consisted of i.b. administration of 0.4 ml of 0.1 N
hydrochloric acid (HCl) for 15 s and neutralized with 0.4 ml of
0.1 N potassium hydroxide (KOH) for 15 s. The bladder was then
drained and flushed with sterile phosphate-buffered saline (PBS).
Histologically, HCl/KOH instillation elicited focal urothelial
denudation with slight submucosal blood vessel dilatation.
Immediately after bladder conditioning, the AY-27 cells were
instilled and left indwelling for at least 1 h. The rats were turned
90° every 15 min to facilitate whole bladder exposure to the
tumour cell suspension. Initially, TCC cell inocula were varied
from 1 ´ 106 to 3 ´ 106 cells to examine dose dependency.
Unconditioned bladders were examined for tumour takes as well.
After 1 h, the catheter was removed and the rats were allowed to
void the suspension spontaneously. After recovery from the anaes-
thetic, the rats were placed into standard cages and monitored
daily for haematuria and general health status. Rats were assessed
for tumour growth by serial MRI at 8–14 days post-inoculation,
and were sacrificed and necropsied at intervals following MRI
detection of tumour growth.
To evaluate the natural course of tumour progression over time,
12 rats inoculated with 1.5 ´ 106 AY-27 cells were followed until
they developed signs of advanced disease. The rats were moni-
tored daily for general health status, and were sacrificed and
necropsied when they had any of the following signs: poor
grooming, lethargy, hunching, or palpable abdominal mass. All
rats were euthanized prior to onset of significant tumour-related
morbidity.640 Z Xiao et al
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MRI protocol
For MRI, the rats were anaesthetized with ketamine and xylazine,
their bladders were then catheterized and moderately distended
with 0.5 ml normal saline. Two rats were simultaneously posi-
tioned supine in an MRI knee coil. Turbo STIR (Short-T1
Inversion Recovery sequence) images (TR = 2647, TE = 20,
TI = 165) were acquired using 205 ´ 256 matrix, with a field of
view of 100 mm, and 0.49 mm ´ 0.39 mm in-plane resolution. A
Philips Gyroscan ACS-II 1.5T clinical magnet was used to
generate 1.8-mm slices with a 0.4-mm interval between slices. No
external marker was required to interpret bladder location, which
was initially determined by serial scanning of the rats in the trans-
verse and sagittal planes. Typically, STIR images were acquired in
both planes, resulting in well defined images capable of moni-
toring tumours nominally 2 mm in diameter. Imaging of the rats
was carried out weekly until sacrificed.
Gross and microscopic histology
Necropsy was performed on all rats. The extent of tumour burden
at necropsy was evaluated by gross and microscopic examination
of the bladder, as well as the organs within the cranial, thoracic and
peritoneal cavities. The presence or absence of tumour was noted,
along with the number of foci, morphology, size and degree of
tumour invasion. On removal, the bladders were reflected open
and examined for tumour distribution and tumour size. Tissue
from the bladders and other organs was fixed in 10% phosphate-
buffered formalin, embedded in paraffin, serially sectioned at
4 mm, and were stained with haematoxylin-eosin (H&E) for
histological examination.
Immunocytochemistry of AY-27 bladder tumour
To confirm that the AY-27 tumour has and retains the TCC pheno-
type after several in vitro and in vivo passages, a three-step,
indirect immunoperoxidase staining of paraffin-embedded bladder
tumour sections with two monoclonal antibodies directed against
cytokeratins 7 and 13 was conducted (Moll et al, 1988).
Cytokeratin 7 has been shown to be expressed in normal human
and rat urothelia, as well as in transitional cell carcinomas, but not
in squamous cell cancer (Moll et al, 1988; Cilento et al, 1994).
Cytokeratin 13 is considered to be a reliable ‘group marker’ for
squamous epithelium from different organs, whereas it is absent in
pure TCC without squamous differentiation (Moll et al, 1988).
Briefly, the 4-mm-thick tissue sections were deparaffinized and
heated (Microwave processor, Model H2500, Energy Beam
Sciences, Inc.) to 100°C for 10 min, and then treated with 0.05%
trypsin for 15 s before adding the antibody. After labelling with the
primary antibody (either anti-cytokeratin 7 or 13, mouse IgG1;
Boehringer Mannheim Biochemica, Germany), biotin-conjugated
second antibody (murine IgG, Dako, USA), and avidin–peroxidase
conjugate (Biogenix, Canada), the sections were incubated with
diaminobenzidine (DAB), and counter-stained with haematoxylin.
For comparison, histological sections of human transitional cell
carcinoma, squamous cell carcinoma, rat normal skin and AY-27
cell monolayer cultures, were stained using identical techniques.
To examine for Fas or Fas-ligand (FasL) expression on AY-27
cells, the cells were grown to approximately 70% confluence in
T-75 flasks, washed once in PBS with 0.04% EDTA, and then
incubated in PBS with 0.04% EDTA for 30 min at 37°C. The cells
were then harvested by gentle pipetting, pelleted by centrifugation,
washed once with PBS, and again pelleted. The cells were then
resuspended in 600 ml immunofluorescence (IF) buffer (1% fetal
bovine serum, 0.02% sodium azide in PBS) and 200-ml aliquots
were transferred to 1.5 ml Eppendorf tubes and placed on ice. Each
aliquoted sample received 1 ml of either anti-Fas (Pharmigen,
USA), anti-FasL (Pharmigen, USA), or isotype-matched control
(X931, Dako, USA) antibody and was incubated for 1 h on ice.
Subsequently, the cells were pelleted, washed twice in IF buffer,
and resuspended in 200-ml IF buffer with 10% normal goat serum
(Dako, USA). Samples were incubated at room temperature for 
10 min, then returned to ice. Each sample received 1 ml of goat
anti-mouse-IgG-FITC (Pharmigen, USA) and was then incubated
on ice in the dark for 1 h. The cells were pelleted, washed twice in
IF buffer, then resuspended in 500 ml of 1% formaldehyde in PBS.
Following the above processing, the samples were analysed imme-
diately using a Becton-Dickinson flow cytometer and CellQuest
software.
RESULTS
Orthotopic bladder tumour establishment
Single-cell suspensions of 1.5 ´ 106 AY-27 cells instilled into
normal (non-conditioned) bladders did not result in tumour estab-
lishment. The establishment of bladder tumours following AY-27
cell instillation into bladders with preconditioned mucosa is
summarized in Table 1. A total of 106 rats were inoculated intra-
vesically with AY-27 cells. Of these rats, four died of complica-
tions related to the anaesthetic or tumour implantation procedure
during initial experiments. The overall tumour establishment was




time of rats No CIS T1/CISb T2 T3 T4 stone rats with
(days) tumour only tumour (%)
12–13 8 3 3 2 0 0 0 0 5/8
16–17 82 2 17 35 23 5 0 7 80 (97%)
22–50 12 0 0 3 3 4 2 4 12/12
Total 102 5 20 40 26 9 2 11 97 (95%)
aCIS: Tumour cells confined to bladder mucosa, no papillary tumour. T1: papillary tumour invading bladder submucosa, but not beyond. T2: papillary tumour
invading one-half of the bladder wall, but not through it. T3: papillary tumour penetrating through the bladder wall, no apparent metastasis. T4: papillary tumour
invading adjacent organs or metastasizing to distant organs. bPapillary tumours were usually accompanied by CIS. If a rat had more than two categories (CIS,
T1, T2, T3, and T4), it was allocated to the highest category.An orthotopic rat bladder TCC tumour model 641
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95% (97/102). Of the 102 remaining rats, eight were sacrificed
12–13 days after tumour cell instillation, three of the eight had no
detectable tumour. Carcinoma in situ and/or T1 bladder tumours
were detected in the remaining five, and none had developed
invasive tumour. Rats inoculated with 1.0 ´ 106 AY-27 cells were
included in this initial group. Another 82 rats were euthanized on
day 16–17 post-implantation following MRI detection of tumour.
Only two were tumour-free, 80 rats (97%) developed various
stages of bladder tumours: 65% (52/80) with superficial tumours
(CIS, T1); 29% with T2; and five out of 80 with T3 bladder
tumours. None of these rats developed distant metastases,
although two had hydroureteronephrosis, with evidence of
secondary infection to tumour obstruction of the ureters. Twelve
rats were followed until they were overtly symptomatic, prior to
being necropsied on day 22–50 (average 35 days) to assess the
natural history of disease progression. All these rats developed
bladder tumours, 66% (9/12) of which were invasive T2 to T4
bladder tumours. Hydroureteronephrosis due to tumour obstruc-
tion was found in four rats. In two of these four rats, tumour cell
metastasis to the common iliac artery lymph nodes was detected.
Tumour seeding of the peritoneum was detected in only one rat.
Gross and microscopic characteristics
Microscopic and gross characteristics of the bladder tumour are
presented in Figure 1A–D. The malignant cellular features of this
bladder tumour included high mitotic activity, high nuclear-to-
cytoplasmic ratio, and marked nuclear pleomorphism. These
cellular characteristics are identical to those observed for the AY-
27 cells in monolayer culture. Different in vitro passage numbers
yielded similar tumour establishment, but with a slight increase in
tumour aggressiveness occurring with later passages. The in vitro
Figure 1 Microscopic and gross features of AY-27 bladder tumours of
different stages. (A) In the early stage, soon after tumour cells establish on
basement membrane where normal urothelium is sloughing (arrows), bladder
CIS replaces normal urothelium and covers partial or entire bladder lumen
surface. There is a moderate increase in the nuclear-to-cytoplasmic (N/C)
ratio in cells. Mitotic figures (arrowheads) are common. (B) Development of
papillary tumour is the characteristic of disease progression in the mid stage.
The papillae are usually short. The N/C ratio of the cells is moderately
increased, the nuclei have slightly irregularly distributed chromatin, and
nucleoli are prominent (Grade II). (C) In later stages, Grade III tumour cells
(*) invade to submucosa and bladder detrusor muscle. There is marked
increase in the N/C ratio in cells which form solid sheets. There is markedly
increased variation in nuclear size and shape, and mitotic figures (arrows)
and nucleoli are frequent and prominent. ‘U’ denotes normal urothelium.
(D) Gross view of bladder papillary tumour at mid stage. A solitary tumour
(*) locates at bladder posterior-left wall with a cauliflower-like configuration.
(A–C) H&E, Bar = 100 mm
A C
B
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doubling time of exponentially growing AY-27 cells was approxi-
mately 24 h.
The microscopic and gross features observed after i.b. AY-27
cell inoculations followed a pattern that may be divided arbitrarily
into three stages: (1) early tumour establishment (post-inoculation
days 1–13); (2) mid stage of i.b. progression (days 14–21); and (3)
advanced i.b. progression and extravesical spread (days 22–50).
Soon after instillation into the bladder, tumour cells implanted on
the basement membrane where the urothelium was denuded.
Tumour cells grew and extended along the basement membrane,
and eventually replaced the surrounding normal urothelium
(Figure 1A). At this early stage, the lesions appeared flat and intra-
epithelial, and were defined as bladder CIS.
During the mid stage, these intra-epithelial lesions developed
into papillary tumour, or invasive disease, probably depending
upon cellular differentiation and host resistance, since in papillary
tumour moderately differentiated cells were predominant (Figure
1B), while in invasive tumour, more poorly differentiated cells
were prominent (Figure 1C). In some cases, lymphocytic and
mononuclear cell infiltration around tumour could be seen. The
papillary tumour configuration appeared similar to that of the
human counterpart. The tumour papillae, however, were shorter
and less branched (Figure 1B), such that the tumour assumed a
broad-based cauliflower-like appearance (Figure 1D). In certain
cases, diffuse, fine granularity of tumour covering the entire
bladder lumen was seen. Twenty-nine per cent of tumour invaded
the submucosa connective tissue and/or superficial detrusor
muscle. Only in a few cases (5/80) did the tumours invade through
the detrusor muscle. Two rats with gross hydroureteronephrosis
were found to have evidence of infection secondary to tumour
obstruction of the distal ureters.
At the advanced stage, tumour cells penetrated the bladder wall
and spread to lymph nodes. The advanced stage was frequently
associated with hydroureteronephrosis which also appeared to be
caused by direct tumour invasion. Infection following tumour
obstruction is the most common life-threatening complication
observed in this model. Tumour was detected in the liver in one
case, with concurrent massive peritoneal seeding and spread of
other visceral organs. In all the rats studied, no evidence of tumour
spread was found in the lung, brain, heart and pericardial cavity.
MRI
Magnetic resonance imaging demonstrated no evidence of tumour
until at least 10 days post-implantation. With further experience,
we found it only necessary to begin MRI at post-implant day 13.
At this time interval, MRI reliably revealed a thin ‘filling defect’
lesion lining the bladder wall (Figure 2A). By post-implant day 16,
part of the bladder lumen was occupied by the ‘filling defect’
lesion (Figure 2B). Necropsy examination revealed a solitary
papillary tumour located on the posterior-left bladder wall (Figure
1D). If invasive tumour developed, MRI showed the bladder
outline was disrupted and retracted by the invading tumour (Figure
2C). The changes seen on MRI correlated well with the extent of
tumour invasion identified histologically.
Immunocytochemistry
Both human and rat urothelia were stained strongly positive with
anti-cytokeratin 7, while only basal and intermediate cells stained
weakly positive with anti-cytokeratin 13. Human TCC cells were
strongly positive with anti-cytokeratin 7 staining, but negative
with anti-cytokeratin 13 staining. The AY-27 tumour cells from
both in vivo bladder tumour and in vitro cell cultures were simi-
larly positive with anti-cytokeratin 7 staining, but negative with
anti-cytokeratin 13 (Figures 1C and 3A–B). The AY-27 bladder
Figure 2 MR images of rat bladders at different post-inoculation days.
(A) A thin ‘filling defect’ lesion (open arrow) lining the posterior bladder wall
13 days following tumour cell instillation. ‘u’ represents the urethra. There is
an air bubble (arrow) locating at the bladder dome. (B) A transverse view
showing a ‘filling defect’ lesion (arrow) arising from the posterior left bladder
wall, protruding into the lumen 16 days post-implantation. The corresponding
tumour is shown in Figure 1D. (C) A sagittal view showing the bladder is
partially filled with tumour (large arrow) that disrupts the bladder outline
(small arrow) with retraction due to tumour invasion at 28 days
post-implantation. ‘S’ denotes the stomach. (A–C) Bar = 10 mm
A
B
CAn orthotopic rat bladder TCC tumour model 643
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tumour cells used in this model, therefore, maintain urothelial
features and demonstrate no evidence of squamous differentiation,
both histologically and immunochemically.
Immunofluorescent flow cytometry provided a rapid assay for
expression of Fas or FasL. Neither Fas nor FasL is expressed on
AY-27 TCC cells, as the fluorescence distribution profiles are
not significantly different among control and treated samples
(Figure 4).
Other findings
Eleven rats out of 102 developed small bladder stones or calcific
encrustation of the tumour surface. Although the reason for
calculus formation was not thoroughly investigated, it was evident
that stone formation correlated directly with the presence of
tumour necrosis, that occurred with heavy tumour burden. Thus,
necrotic tumour appeared to be providing a nidus for stone forma-
tion from the lithogenic urine.
Approximately 2 weeks following tumour implantation, some
rats failed to gain body weight. These animals maintained their
initial body weight, but did not grow as expected, presumably due
to tumour growth. In the few animals with advanced stage T4
disease, the tumour mass could be detected by palpation of the
lower abdomen.
Flank tumour growth
Tumour establishment following subcutaneous (s.c.) injection of
cell suspension (ten rats), or implantation of 2 mm3 tumour chunks
(30 rats) was 100%. Over a period of 4 weeks, the tumours
Figure 3 Immunoperoxidase staining of formalin-fixed, paraffin-embedded rat bladder sections adjacent to the tissue section shown in Figure 1C. (A) Staining
with anticytokeratin 7 shows that both normal urothelium (U) and tumour cells (*) are positive (dark brown). (B) Staining with anti-cytokeratin 13 shows that only
basal and intermediate cells (arrows) of normal urothelium are weakly positive (light brown), while tumour cells (*) are negative. Immunochemical staining was
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Figure 4 Fas and FasL expression on AY-27 TCC cells. Cells were incubated first with either anti-Fas (A), anti-FasL (B), or isotype-matched mouse IgG
(control), then with goat anti-mouse-Ig-FITC. Samples were read on the FL 1 parameter using a flow cytometer (see Materials and Methods for details). The
fluorescence distribution profiles are not significantly different among control (I) and treated samples (II)
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progressively grew to approximately 15 mm in diameter (about
1700 mm3). The tumour-volume-doubling time was approximately
4 days. Upon dissection, the tumours demonstrated a smooth thin
capsule, with a well-vascularized surface and a zone of central
necrosis. The tumour architecture was solid, monotonous sheets of
TCC cells without papillary growth. No evidence of distant metas-
tasis was found; however, there was evidence of local tumour
invasion into the underlying striated muscle in two rats.
DISCUSSION
Our primary objective was to develop a bladder tumour model for
whole bladder PDT and other i.b. therapies. This requires an ortho-
topic, superficial and purely TCC model with a reasonable bladder
volume and urethral caliber to introduce the laser fibre or other
therapeutic agents into the bladder. Spontaneously arising rodent
bladder tumours are rare (van Moorselaar et al, 1993). A suitable
rat model may meet these criteria, since carcinogen induced
primary bladder tumours closely parallel the human disease in
both morphology and tumour biology (Oyasu, 1995). However,
several limitations of previously described models exist. For
example, induction of primary bladder tumours requires several
months, with both TCC and squamous carcinoma being induced,
and tissues other than urothelium also being transformed (Erturk
et al, 1967, 1969, 1970; Herman et al, 1985; Oyasu, 1995; Stocker
et al, 1997). The subcutaneous tumour model is unsuited to i.b.
anti-tumour therapies, not only due to its heterotopic growth, but
also due to its dissimilarities in biological behaviour to the clinical
disease, as observed in this study. Therefore, ideally, a trans-
plantable orthotopic rat bladder tumour model appears more rele-
vant as an experimental tool for testing new antineoplastic agents
provided it is easy to establish and highly reproducible. Soloway
(1977) showed that by traumatization of the bladder mucosa by
MNU 48 h prior to tumour cell inoculation, the bladder tumour
cells (MBT-2) could be implanted intravesically in mouse bladder
mucosa. He reported about 60% tumour takes. Ibrahiem and
colleagues (1983) injected rat bladder tumour cells into the bladder
muscle to develop an invasive bladder tumour model after failure
to implant the tumour cells on the bladder mucosa using Soloway’s
technique. Their model did not closely mimic the human counter-
part because the tumour was actually invasive and covered with
normal bladder mucosa (Ibrahiem et al, 1983; Harney et al, 1991;
Iinuma et al, 1995). Chin and colleagues (1991) reported that
tumour cells could be efficiently inoculated in mouse bladder
mucosa that was pretreated with mild HCl/KOH. They reported
about 80% tumour growth. However, the rat model, because of its
size, is easier to work with for i.b. therapies and, furthermore, it
may parallel the human disease processes better than a mouse
model (Ohtani et al, 1986; Oyasu, 1995). Detailed characteristics
of a transplantable orthotopic rat bladder tumour model, to the best
of our knowledge, have not been described.
Using the AY-27 cell line and a modification of the techniques
previously described by Chin et al (1991) for the MBT-2 model,
we have developed and characterized a highly reproducible, trans-
plantable, purely TCC rat orthotopic bladder tumour model. The
procedures are not technically complicated, are well tolerated by
the animals and result in minimal morbidity associated with occa-
sional mild haematuria subsequent to tumour cell instillation. The
fact that tumour cells used for i.b. instillation originated from cell
cultures rather than directly from solid tumour fragments, might
contribute to the high tumour establishment observed. Tumour
cells prepared from tumour fragments may also contain stromal
cells, lymphocytes, etc., and their viability might be compromised
due to mechanical or enzymatic treatment. Initially, tumour cell
suspensions prepared directly from tumour fragments were used
for both s.c. injection and i.b. instillation. The resulting tumour
grew slower with lower tumour establishment (data not shown).
Single-cell suspensions of AY-27 cells instilled in normal (uncon-
ditioned) bladder did not elicit tumour establishment. Prior to 13
days post-inoculation, all tumours detected are superficial (T1,
CIS). The relatively lower tumour establishment in this group may
be explained either by: (1) small early CIS-like lesions escaping
detection on histological examination; or (2) this group including
three rats inoculated with a lower dose (1.0 ´ 106) of AY-27 cells.
In a group of animals sacrificed on days 16–17 post-inoculation,
the tumour establishment is 97% (80/82), with 65% being super-
ficial (T1, CIS), 29% superficially invasive (T2), and 6% deeply
invasive (T3) disease. Thus 14–16 days post-inoculation seems to
be the most suitable time for i.b. therapies such as chemotherapy,
immunotherapy or whole bladder PDT. With time, there is
progression of the disease process with invasive tumours detected
in 66% of the animals followed 21–50 days post-tumour inocu-
lation.
Recently, we also have established an orthotopic nude rat model
xerografted with human bladder TCC cells (MGH-U3) using
similar procedures described in this study (data not shown). While
this tumour model may better represent the cellular biology of
human disease, greater time, cost and labour are necessary to
maintain the nude rat model than the syngeneic model. As well,
the nude model is not appropriate for active immunotherapy like
BCG instillation, which currently is the most effective clinical
therapy for bladder CIS.
In clinical practice, human bladder carcinoma is commonly
classified into three types: CIS, superficial papillary and invasive
carcinomas. The superficial papillary tumours frequently recur
after TUR, but the prognosis is good. The invasive tumour has a
very poor prognosis with the median survival being approximately
1 year despite the use of aggressive regimens (Roth, 1996).
Whether the carcinogenesis of these two entities is different has
yet to be determined. Studies on animals using bladder carcino-
gens suggest that both papillary and invasive tumours may be
derived from CIS depending on cellular differentiation (Ohtani
et al, 1986; Oyasu et al, 1987; Oyasu, 1995). In addition, Orozco et
al (1994) analysed 102 patients with primary or secondary bladder
CIS, and suggested that host resistance to local progression deter-
mined the outcome of CIS, since bladder CIS is cytologically
identical to high-grade papillary and invasive TCC. Droller et al
(1982) also found that tumour development was accompanied by
decreased lymphocyte cytotoxicity against bladder tumour in rats.
Our observations in the transplantable tumour model also support
these findings. Bladder CIS may develop to papillary or invasive
tumours depending on both cellular differentiation and host resis-
tance to disease progression, since the cytology of papillary
tumours is similar to that of CIS. The latter is usually thought to be
the preliminary stage of invasive diseases. The course of tumour
progression observed in our model mimics the clinical situation
resulting from viable tumour cell implantation at the time of TUR
or prior. These findings may also suggest that the AY-27 cells are
heterogeneous.
In addition to cellular differentiation and host resistance, recent
evidence shows that cell-to-cell and cell-to-substrate interactions
also play an important role in tumour progression. InhibitingAn orthotopic rat bladder TCC tumour model 645
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metastasis by interfering with cancer cell adhesion may be a future
therapeutic option, since tumour cells establish bonds with other
cells and extracellular matrix by cell adhesion molecules
(Ruoslahti, 1996). Cell adhesion molecules consist of multimolec-
ular protein complexes of transmembrane adhesion receptors
anchoring intracellular cytoskeletal structural proteins and signal
transduction molecules (Yamada et al, 1997). Our model could
potentially be utilized to conduct studies of using biological agents
to prevent tumour cell seeding by interfering cell adhesion or
inducing apoptosis. FasL, a cell surface molecule belonging to the
tumour necrosis factor family, binds to its receptor Fas (a type I
membrane protein), thus inducing apoptosis of Fas-bearing cells
(Nagata et al, 1995). It has been hypothesized that i.b. administra-
tion of FasL could be employed as a treatment option for bladder
TCC. In the present study, the expression of Fas and FasL on
AY-27 cells has been investigated to explore whether the model is
suitable for therapy with Fas or FasL. Preliminary evidence
suggests that neither marker is expressed in the absence of some
form of induction.
Cytokeratins are part of the intermediate filament system of the
cytoskeleton (Steinert et al, 1988). The synthesis of cytokeratins is
usually maintained during malignant transformation, and this
feature serves as one of the hallmarks of epithelium-derived
tumours (Tseng et al, 1982), including tumours of the urinary tract
(Moll et al, 1982, 1988; Letocha et al, 1993; Cilento et al, 1994).
Cytokeratin 7 has been considered a urothelial marker (Cilento
et al, 1994), while cytokeratin 13 is a squamous cell marker with
trace amounts of component 13 expressed in basal and interme-
diate cells of human urothelium and low-grade TCC (Moll et al,
1988). Immunocytochemical studies show that the AY-27 rat
bladder tumours retain TCC features, without squamous cell
differentiation. The latter, if present, usually associates with
high-grade (G2–G3), invasive TCC (Oyasu, 1995). Since squa-
mous carcinoma may respond differently to anticancer therapies
than TCC carcinoma, this purely TCC tumour model is ideal
for preclinical evaluation of anti-tumour therapies for human
bladder TCCs, the most common type of cancers arising from
the urothelium.
MRI provides a non-invasive imaging modality that is useful to
detect early superficial papillary tumour and monitor tumour
growth in rodent models. Previously, confirmation of successful
tumour implantation in rodents was based on the detection of a
palpable suprapubic mass, gross haematuria, weight loss in the
animals, or on a transillumination technique by periodic surgical
exposure of the bladder (Ibrahiem et al, 1983). In the present
study, only two rats with advanced (stage T4) tumours had a
palpable suprapubic mass. The average weight loss was insignifi-
cant (0.2%). The changes shown on MRI correlated well with the
extent of tumour invasion identified histologically. However, once
this tumour model had been characterized for growth kinetics,
regular monitoring with MRI added little benefit because of the
high reproducibility of this model.
In conclusion, the distinct advantageous features of this model
system include: (1) purely TCC carcinomas growing orthotopi-
cally in the bladder lumen; (2) highly reproducible tumour growth
in a relatively short time; (3) resemblance to high-grade human
TCC in both morphology and tumour biology; and (4) utility to
test varying intravesical therapies such as chemotherapy, active
and passive immunotherapies and whole bladder PDT. This 
model has been used for PDT (Xiao et al, 1998) and BCG
immunotherapy of bladder cancer in our laboratory.
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